| Events | Person-years | Incidence | Previous zoster to index datea | Time-to-eventb | aHR (95% CI) | P value | aHR (95% CI) | P value |
---|---|---|---|---|---|---|---|---|---|
Etanercept (n=311) | 71 (22.8) | 1004 | 70.7 | 1.9 (0.8–3.3) | 1.7 (0.8–3.3) | Reference |  | 1.22 (0.75–2.00) | 0.421 |
Infliximab (n=186) | 35 (18.8) | 435 | 80.5 | 2.2 (1.1–3.8) | 1.8 (0.4–3.1) | 0.88 (0.55–1.41) | 0.599 | 1.08 (0.62–1.87) | 0.784 |
Adalimumab (n=412) | 96 (23.3) | 1018 | 94.3 | 2.2 (0.9–3.9) | 1.2 (0.5–2.6) | 1.22 (0.85–1.75) | 0.276 | 1.50 (0.93–2.40) | 0.094 |
Golimumab (n=190) | 26 (13.7) | 310 | 83.9 | 3.2 (1.5–4.7) | 0.9 (0.5–1.6) | 0.54 (0.27–1.09) | 0.084 | 0.66 (0.32–1.37) | 0.268 |
Tocilizumab (n=247) | 34 (13.8) | 392 | 86.7 | 3.0 (1.5–4.8) | 0.9 (0.3–1.8) | 0.95 (0.57–1.58) | 0.838 | 1.16 (0.67–2.00) | 0.590 |
Tofacitinib (n=143) | 18 (12.6) | 97 | 185.6 | 3.9 (2.0–6.2) | 0.3 (0.1–0.8) | 3.01 (1.49–6.11) | 0.002 | 3.69 (1.77–7.69) | <0.001 |
Abatacept (n=228) | 33 (14.5) | 394 | 83.8 | 2.9 (1.4–4.6) | 1.1 (0.5–2.3) | 0.82 (0.50–1.34) | 0.421 | Reference |  |